SpringWorks TherapeuticsSWTX
About: SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.
Employees: 368
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
75% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 7 (+3) [Q4]
42% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 62
13% more capital invested
Capital invested by funds: $2.58B [Q3] → $2.92B (+$341M) [Q4]
0.3% more ownership
Funds ownership: 108.42% [Q3] → 108.72% (+0.3%) [Q4]
10% less first-time investments, than exits
New positions opened: 38 | Existing positions closed: 42
4% less funds holding
Funds holding: 223 [Q3] → 215 (-8) [Q4]
17% less call options, than puts
Call options by funds: $10.4M | Put options by funds: $12.6M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Robert Burns 16% 1-year accuracy 28 / 172 met price target | 95%upside $74 | Buy Reiterated | 24 Feb 2025 |
Wedbush David Nierengarten 34% 1-year accuracy 40 / 119 met price target | 103%upside $77 | Outperform Reiterated | 12 Feb 2025 |
Evercore ISI Group Cory Kasimov 31% 1-year accuracy 5 / 16 met price target | 71%upside $65 | Outperform Maintained | 12 Feb 2025 |
Financial journalist opinion
